Researchers uncover alarming link between commonplace household chemicals and diabetes: 'A risk factor for several chronic diseases'
Common household exposures could raise your chances of developing diabetes via "forever chemicals," Mount Sinai researchers have found.
What's happening?
A new investigation examined blood samples from 360 study participants in New York City, half of whom had recently received diabetes diagnoses and half of whom hadn't.
The research team measured PFAS contamination levels. PFAS, or "forever chemicals," are man-made compounds found in cookware coatings, furniture treatments, and waterproof gear.
The researchers found that each increase into a different range of chemical exposure corresponded with a 31% jump in diabetes risk. According to a summary of the study, these substances can interfere with the production of amino acids and how the body handles medicines, which disrupts blood sugar management.
The chemicals persist in our surroundings and in human tissue because they resist breaking down naturally.
Why is this discovery important?
PFAS contamination is possible through common household items and drinking water. These compounds accumulate in our bodies over decades, potentially triggering changes in metabolism that lead to long-term illnesses.
"Mounting research suggests that PFAS are a risk factor for several chronic diseases, such as obesity, liver disease, and diabetes," said Dr. Damaskini Valvi, who contributed to the research.
Rising diabetes rates strain healthcare systems and families nationwide. Understanding contamination sources helps doctors develop better prevention strategies, particularly for vulnerable communities that face higher exposure rates.
This research connects pollution to public health outcomes, showing how chemical contamination translates to real medical consequences.
What's being done about PFAS exposure?
Scientists are calling for expanded research combining contamination and genetic data to understand how chemical exposures interact with metabolism across different life stages. This knowledge could lead to targeted interventions for at-risk populations.
Do you worry about having toxic forever chemicals in your home?
Majorly
Sometimes
Not really
I don't know enough about them
Click your choice to see results and speak your mind.
You can reduce your exposure by choosing PFAS-free products when shopping for cookware, carpets, and clothing. Look for items labeled as not being water- or stain-resistant.
Support legislation limiting PFAS use in consumer goods by contacting your representatives. Several states have already passed restrictions on these chemicals in food packaging and firefighting foam.
Consider filtering your drinking water, as many municipal systems contain PFAS contamination. Reverse osmosis and activated carbon filters help remove these compounds.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
From Pain Point to Game Changer: Welove Creations Wins 2025 Red Dot Design Award, Setting a New Standard for the Future of Hearing Protection
IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Welove Creations proudly announces that its innovative Welove Earplugs have won the prestigious Red Dot Design Award 2025, affirming its place among the world's leading hearing protection solutions. 'A harmonious combination of comfortable fit, sophisticated functionality, and attractive design. The practical UV-sanitizing case is another impressive detail.' The remarkable quality and design won over the international Red Dot Jury. Ergonomically crafted to redefine earplug comfort, Welove Earplugs are the world's first to combine a design that mirrors the contours of the ear with a UV-sanitizing case, featuring SGS-certified 18 dB NRR noise reduction — a breakthrough in hearing safety. The design offers a virtually weightless feel with effective noise cancelling, ensuring safe, secure, and hygienic comfort for long-term wear — ideal for restful sleep, deep focus, stress-free travel, and all-day comfort. Recognized as the best earplugs for sleeping, Welove Earplugs address long-standing issues of discomfort, poor fit, and hygiene — challenges that have plagued users for years. This innovative solution is rapidly reshaping the hearing protection market, elevating earplugs from disposable items to daily essentials. Trusted by sleep experts, healthcare professionals, musicians, travelers, and even former Olympians, Welove Earplugs are now showcased at the Red Dot Design Museum in Essen, Germany, which attracts over 150,000 design enthusiasts each year, joining the ranks of globally recognized icons of innovation. The craftsmanship behind the award: after more than a decade of tinnitus and noise sensitivity, the founder struggled to find earplugs she could wear comfortably day and night. She assembled a three-person team and, over 450 days of relentless refinement, created the industry's most comfortable earplugs for prolonged wear, instantly ranking among the world's finest upon launch. "Peace begins with care, and love drives everything we do," says the Welove team. "This award further reinforces our mission to craft high-quality products that inspire joy and connection, helping people live life to the fullest. Our dove logo embodies this belief: in a chaotic world, find peace in love.' With growing global recognition, Welove Creations remains committed to dedication, expertise, and sincerity — proving that with love and the courage to innovate, even a small team can set new standards on the world stage. About us: hello@ A photo accompanying this announcement is available at
Yahoo
15 minutes ago
- Yahoo
The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know
Key Points Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline. The company looks attractively valued following its underperformance over the past 12 months. 10 stocks we like better than Novo Nordisk › The past 12 months haven't been great for Novo Nordisk (NYSE: NVO). Its shares peaked last year and have been in a downward spiral due to unimpressive financial results, clinical setbacks, and mounting competition in its core areas of expertise. However, Novo Nordisk is looking to bounce back. Recent regulatory progress could be a positive step in that direction. Here's what investors need to know. Another important approval On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a household name, famous for helping people manage their weight, but this new indication could be a significant development. Here's why. MASH is a disease characterized by the accumulation of fat in the liver, leading to inflammation. According to some estimates, 22 million adults in the U.S. have MASH, although fewer, about 9 million, have clinically meaningful liver disease. That's not an insignificant number, and one might think that, given this large addressable market, there are many approved therapies for MASH. But that's not the case. Developing effective treatments has proven to be surprisingly challenging. Last year, the FDA approved the first therapy specifically for MASH. Now, Wegovy has become the first GLP-1 medicine to earn that indication. Although there are other treatments in development, Wegovy could carve out a decent market for itself in MASH, especially since it posted phase 3 results comparable to those of its only competitor on the market (for now): Rezdiffra, marketed by Madrigal Pharmaceuticals. Novo Nordisk is a significantly larger company with more funds, a larger marketing budget, and a larger sales team than its smaller peer. What will be the demand for Wegovy in MASH be? We can gather some clues from Rezdiffra's launch, which is going extremely well. About a year after it hit the market, Rezdiffra generated $212.8 million in revenue in the second quarter -- that's impressive and points to a massive demand for the medicine. Yet, Madrigal has barely scratched the surface of the addressable market. As of June 30, it had treated just over 23,000 patients. Wegovy's launch in MASH should be even smoother since it isn't starting from scratch -- it's already been on the market for several years. In my view, this new indication could add over $1 billion in sales to Wegovy's total within the next few years, especially because it's also being considered for approval for MASH in Japan and the European Union. It's also worth pointing out another development that helped jolt Novo Nordisk's stock price. The company is partnering with GoodRx to offer Ozempic at a reduced cost for patients who pay out of pocket. This move should help it deal with some companies that sell compounded versions of Ozempic for less. Is Novo Nordisk's stock a buy? Wegovy could earn yet another important label expansion by next year, although in a different version. Earlier this year, Novo Nordisk requested approval for an oral formulation of the medicine for weight loss. That could also move the needle for the pharmaceutical giant. An oral version would be faster and cheaper to produce, easier to transport, and thus more cost-effective to manufacture at scale. The previous shortages Wegovy dealt with would be far less likely to occur with an oral formulation. Notably, it would mark yet another breakthrough for Novo Nordisk. There is currently no oral GLP-1 medication approved for weight loss -- the drugmaker's own Rybelsus, an oral GLP-1 product, is indicated only for diabetes. Meanwhile, Novo Nordisk's financial results remain strong. In the first half of the year, net sales grew by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit of 55.5 billion DKK ($8.7 billion) rose 22% compared to the year-ago period. Furthermore, Novo Nordisk has an attractive pipeline. CagriSema, a next-generation GLP-1 therapy whose phase 3 results were strong (if not as strong as the market had hoped), appears poised to become a blockbuster. Some analysts predict that it will generate $15.2 billion in revenue by 2030. Elsewhere, Novo Nordisk's amycretin, another investigational weight loss therapy, recently started phase 3 studies in both oral and subcutaneous formulations. Despite recent clinical setbacks, Novo Nordisk's pipeline should earn some significant wins in the next few years, particularly since the company has been strengthening it through licensing deals. Lastly, Novo Nordisk stock looks reasonably valued. The company is trading at 13.5 times forward earnings, compared to an average price-to-earnings ratio of 16.5 for the healthcare industry. At current levels, the stock could deliver superior returns to investors who initiate positions today. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,624!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,117!* Now, it's worth noting Stock Advisor's total average return is 1,052% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Backpack Healthcare Secures $3 Million Contract to Expand Mental Health Services to 150,000+ Students with Scalable Hybrid Model
WASHINGTON, Aug. 21, 2025 /PRNewswire/ -- In response to impending Medicaid policy shifts, Backpack Healthcare has been awarded a $3 million contract, funded by the Maryland Community Health Resources Commission (CHRC) through the Maryland Consortium on Coordinated Community Supports, to provide comprehensive mental health services to over 150,000 students across several school districts. This funding supports Backpack's mission to deliver accessible, scalable mental health support at a critical time. The hybrid model, combining in-person and telehealth options, positions Backpack as a thought leader in adapting to changes in behavioral health policy and offers a scalable solution for school systems nationwide. The contract will provide critical support through individual and group therapy, peer coaching, caregiver wellness workshops, and substance use prevention groups in schools across both counties. This initiative is part of the broader Blueprint for Maryland's Future, which addresses the growing mental health needs of students and offers a model for other districts to follow in preparing for future Medicaid policy adjustments. "The Consortium is pleased to continue our partnership with Backpack Healthcare to support the mental health and wellbeing of Maryland students," said Consortium Chair David Rudolph. "We look forward to working with Backpack as they expand their services through this grant." This agreement is part of a broader effort to help schools adapt to funding shifts and strengthen behavioral health services. Backpack Healthcare will serve over 150,000 students in Baltimore and Howard County, improving access to essential mental health services. In addition to the contract, Backpack Healthcare has released a White Paper titled "Meeting the Moment: How School-Based Mental Health Services Improve Access and Outcomes," providing evidence-based insights into the effectiveness of these services. "We've seen the impact school-based mental health services can have in Howard County, and we're excited to expand that success with Baltimore County," said Jay Taylor, Chief Growth Officer at Backpack Healthcare. "The need for accessible, stigma-free support has never been greater, and we're proud to help meet it. Together, we have a unique opportunity to reach more students, remove barriers to care, and ensure every young person has the support they need to thrive academically, emotionally, and socially." This expansion not only serves existing districts but also aims to attract new partnerships with other school systems facing similar challenges. As districts prepare for Medicaid policy changes, Backpack Healthcare is ready to meet these needs with a proven, cost-effective model. For more information about Backpack Healthcare's services, including how to implement these solutions in your district, or to download the white paper, visit or contact partners@ About Backpack HealthcareBackpack Healthcare is a leading provider of innovative mental health services, focused on supporting children, teens, and families. By leveraging school-based programs and technology, Backpack Healthcare is making mental health care more accessible and effective, helping students thrive academically and emotionally. About the Maryland Community Health Resources Commission: The grant was awarded by the Maryland Community Health Resources Commission (CHRC), established by the Maryland General Assembly in 2005 to expand access to health services in underserved communities. Since its inception, the CHRC has awarded over 980 grants totaling over $392 million in funding, supporting programs in every jurisdiction of the State. These programs have collectively served more than 770,000 Marylanders. More information about the CHRC can be found at this URL: About the Maryland Consortium on Coordinated Community Supports: The Maryland Consortium on Coordinated Community Supports (Consortium) was established by the Maryland General Assembly as part of the Blueprint for Maryland's Future to create a statewide framework to increase access to coordinated non-stigmatized, comprehensive behavioral health services statewide. The CHRC is the fiscal agent and provides staff support for the Consortium. More information about the Consortium can be found at this url: Media Contact:marketing@ View original content: SOURCE Backpack Healthcare (Formerly Youme Healthcare) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
